<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ920124-0044</DOCNO><DOCID>920124-0044.</DOCID><HL>   Business Brief -- Genzyme Corp.:   Cystic Fibrosis Drug Gets   Orphan-Drug Designation</HL><DATE>01/24/92</DATE><SO>WALL STREET JOURNAL (J), PAGE B4</SO><CO>   GENZ NEOZ</CO><MS>TECHNOLOGY (TEC)</MS><IN>BIOTECHNOLOGY (BTC)MEDICAL andamp; BIOTECHNOLOGY, GENETIC RESEARCH, PROSTHETICS (MTC)</IN><GV>FOOD AND DRUG ADMINISTRATION (FDA)</GV><RE>MASSACHUSETTS (MA)NORTH AMERICA (NME)UNITED STATES (US)</RE><LP>   Genzyme Corp., Cambridge, Mass., said it receivedorphan-drug designation from the Food and Drug Administrationfor a genetically engineered drug to treat cystic fibrosisthat the company is developing.   The drug, called recombinant cystic fibrosis transmembraneconductance regulator, or r-CFTR, is a bioengineered versionof naturally occurring protein that is defective in peoplewith the inherited disease. Genzyme hopes to use r-CFTR as amedicine to replace the defective protein in people withcystic fibrosis.</LP><TEXT>   Cystic fibrosis, which affects about 30,000 people in theU.S., is a fatal inherited disorder that clogs the airwayswith thick mucous and causes respiratory and digestiveproblems.   Orphan-drug status qualifies the owner of its patent forexclusive marketing rights for seven years, subject to FDAapproval of the owner's new drug application. Genzyme isdeveloping r-CFTR with Neozyme Corp., a research anddevelopment company that Genzyme formed in 1989.</TEXT></DOC>